{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:16:33Z","timestamp":1782738993884,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.lungcan.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T11:14:54Z","timestamp":1583579694000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer"],"prefix":"10.1016","volume":"143","author":[{"given":"Daniel","family":"Sheinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Bruce","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Scott","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.03.005_bib0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hoc.2016.08.012","article-title":"Diagnosis and treatment of ALK positive NSCLC","volume":"31","author":"Arbour","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0010","series-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer","author":"Ettinger","year":"2019"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semcancer.2016.08.007","article-title":"ALK mutation and inhibition in lung cancer","volume":"42","author":"Le","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0030","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","article-title":"Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population","volume":"15","author":"Rodig","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0035","series-title":"Alecensa (alectinib) Prescribing Information","author":"Hoffmann-La Roche","year":"2017"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0040","series-title":"ZYKADIA (ceritinib) Prescribing Information","year":"2019"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0045","series-title":"XALKORI (crizotinib) Prescribing Information","year":"2019"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0050","series-title":"Lorbrena (lorlatinib) Prescribing Information","year":"2018"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0055","series-title":"ALUNBRIG (brigatinib) Prescribing Information","year":"2018"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0065","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0070","doi-asserted-by":"crossref","first-page":"v602","DOI":"10.1093\/annonc\/mdz260.006","article-title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced AL\u2026","volume":"30","author":"Mok","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1200\/PO.18.00159","article-title":"ALK testing trends and patterns among community practices in the United States","author":"Illei","year":"2018","journal-title":"JCO Preci.s Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.03.005_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213209","article-title":"Time to initial cancer treatment in the United States and association with survival over time: an observational study","volume":"14","author":"Khorana","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0085","unstructured":"Flatiron Health database (https:\/\/flatiron.com\/real-world-evidence\/), April 2018, mortality v2.0, Real-world Progression."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0090","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jclinepi.2003.07.012","article-title":"Modeling recurrence in colorectal cancer","volume":"57","author":"Dancourt","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2188\/jea.JE20130164","article-title":"Validation of methods to control for immortal time bias in pharmacoepidemiologic analysis of renin-angiotensin system inhibitors in type 2 diabetes","volume":"24","author":"Yang","year":"2014","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year mark landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0110","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0115","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2014.57.3055","volume":"32","author":"Leighl","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/JTO.0b013e318290868f","volume":"8","author":"Lindeman","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0135","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0140","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/cam4.659","article-title":"Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients","volume":"5","author":"Cui","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s10549-011-1662-4","article-title":"The effect of delays in treatment for breast cancer metastasis on survival","volume":"130","author":"Jung","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0150","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0194599818803330","article-title":"Impact of delay in treatment initiation on overall survival in laryngeal cancers","volume":"160","author":"Kompelli","year":"2019","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0155","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.1038\/s41598-019-46736-1","article-title":"The influence on survival of delay in the treatment initiation of screening detected non-symptomatic breast cancer","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/JCO.2015.61.5906","article-title":"Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States","volume":"34","author":"Murphy","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0165","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.6004\/jnccn.2012.0130","article-title":"Non-small cell lung cancer. Clinical practice guidelines in oncology","volume":"10","author":"Ettinger","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2015.0071","article-title":"Non-small cell lung cancer, Version 6.2015. Featured updates to the NCCN guidelines","volume":"13","author":"Ettinger","year":"2015","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0175","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.3747\/co.23.3243","article-title":"Effect of chemotherapy on health-related quality of life among early-stage ovarian cancer survivors: a study from the population-based PROFILES registry","volume":"23","author":"Bhugwandass","year":"2016","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4048\/jbc.2013.16.2.229","article-title":"Does chemotherapy really affect the quality of life of women with breast cancer?","volume":"16","author":"Hwang","year":"2013","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.lungcan.2020.03.005_bib0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3389\/fonc.2018.00557","article-title":"ALK inhibitors in the treatment of ALK positive NSCLC","volume":"8","author":"Khan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2020.03.005_bib0190","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.21037\/tlcr.2018.03.10","article-title":"Quality of life for non-small cell lung cancer patients in the age of immunotherapy","volume":"7","author":"Ramirez","year":"2018","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220303214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:39:15Z","timestamp":1759235955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220303214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":38,"alternative-id":["S0169500220303214"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}